Press release
Investigation announced for Investors in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) over possible Violations of Securities Laws
An investigation for investors in BridgeBio Pharma, Inc. (NASDAQ: BBIO) shares over potential securities laws violations.
Investors who purchased shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm focuses on whether a series of statements by BridgeBio Pharma, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.
Palo Alto, CA based BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers.
On June 5, 2024, BridgeBio Pharma, Inc. issued a press release "announc[ing] sustained positive results from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, demonstrating continued potential best-in-class efficacy and an encouraging safety profile." Despite the study's ostensibly positive results, a Pipe Sandler analyst compared infigratinib to Voxzogo, an already approved drug produced by BioMarin Pharmaceutical Inc., opining that BridgeBio's drug "does not appear well-differentiated from Voxzogo" and that "without any clinical differentiation, we see the competitive threat as mixed."
Shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) declined from $31.16 per share on May 16, 2024, to $26.53 per share on June 10, 2024.
Those who purchased shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Investors in shares of BridgeBio Pharma, Inc. (NASDAQ: BBIO) over possible Violations of Securities Laws here
News-ID: 3540080 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for BridgeBio
Achondroplasia Market Overview: Epidemiology, Treatment Landscape, Key Players | …
DelveInsight's Achondroplasia Market Insights, Epidemiology, and Market Forecast 2034 report provides a detailed outlook of the current and future Achondroplasia treatment market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future Achondroplasia market share of all therapies.
Achondroplasia treatments, including VOXZOGO (vosoritide), RBM-007, SAR-442501, low-dose infigratinib, and others, are anticipated…
Primary Hyperoxaluria Clinical Trials, Companies, Therapeutic Assessment, Therap …
DelveInsight's, "Primary Hyperoxyaluria - Pipeline Insight, 2025" report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in Primary Hyperoxyaluria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, the Primary Hyperoxaluria pipeline features over 6…
Achondroplasia Market: Epidemiology, Therapies, Companies, DelveInsight | Ascend …
Achondroplasia therapies, such as VOXZOGO (vosoritide), RBM-007, SAR-442501, Low dose infigratinib, and others, are expected to boost the Achondroplasia Market in the upcoming years.
DelveInsight has launched a new report on "Achondroplasia - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Achondroplasia, historical and forecasted epidemiology as well as the Achondroplasia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and…
KRAS Inhibitors Market Top Companies Study - Amgen, Boehringer Ingelheim, Bridge …
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global KRAS Inhibitors Market - (By Cancer Type (Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Others), By End-Use (Clinic Laboratories, Cancer Diagnostic Centers, Hospitals, Cancer Research Institutes, Academic Institutions, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
According to the latest research by InsightAce Analytic, the Global KRAS Inhibitors Market is valued at US$ 97.8 Mn…
Hypoparathyroidism Market Growth Anticipated by 2034, DelveInsight | Companies: …
Rising cases of hypoparathyroidism across different regions are driving the demand for advanced diagnostic and treatment options in the hypoparathyroidism market. This growing need is contributing to the overall expansion of the market.
The Hypoparathyroidism Market Report 2034 [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] by DelveInsight provides an in-depth analysis of current treatment practices for hypoparathyroidism, upcoming drugs in the pipeline, market shares of individual therapies, and forecasts the growth trajectory of the hypoparathyroidism market from…
Hypoparathyroidism Market Growth Anticipated by 2034 | Companies includes Takeda …
Rising cases of hypoparathyroidism across different regions are driving the demand for advanced diagnostic and treatment options in the hypoparathyroidism market. This growing need is contributing to the overall expansion of the market.
The Hypoparathyroidism Market Report 2034 [https://www.delveinsight.com/report-store/hypoparathyroidism-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] by DelveInsight provides an in-depth analysis of current treatment practices for hypoparathyroidism, upcoming drugs in the pipeline, market shares of individual therapies, and forecasts the growth trajectory of the hypoparathyroidism market from…
